Cidichem S.R.L.

Cidichem S.R.L. Corbi Division, an Italian limited liability partnership headquartered in Naples, supplies chemical analyzers, laboratory reagents, and medical consumables to the U.S. Navy and Defense Health Agency as a prime contractor on full-and-open delivery orders and indefinite delivery contracts, with no subcontract footprint or set-aside designations.

The vendor's federal customer base is concentrated entirely within the Department of the Navy. The Bureau of Medicine and Surgery accounts for 46 of 54 total awards and $20.2 million of the $21.1 million combined potential value (96% of the portfolio), serving Navy and Marine Corps medical facilities in Italy. Naval Supply Systems Command holds four additional awards valued at $589 thousand, and the Defense Health Agency holds one award for $298 thousand. This concentration reflects Cidichem's position as a regional supplier of medical laboratory equipment and analytical consumables to support U.S. military medical operations in the Mediterranean theater.

Cidichem operates entirely through Navy single-award indefinite delivery contracts. The top five parent vehicles are Navy IDIQs: Indefinite Delivery Contract N6817106D0020 (23 task orders, $12.2 million combined potential value), N6817112D0003 (7 task orders, $971 thousand), N6817116D0032 (4 task orders, $1.2 million), N6817120D0001 (4 task orders, $842 thousand), and N6817123D0004 (4 task orders, $1.2 million). The largest active vehicle is a $1.22 million single-award IDIQ awarded April 1, 2023, and extending through September 30, 2027, under which Cidichem has delivered two orders: a $256,394 delivery order for chemical analyzers and supplies awarded October 1, 2023, and a $514,991 delivery order with schedule revision authority awarded October 1, 2024. A more recent $297,959 delivery order was awarded November 10, 2025, by the Defense Health Agency, also for chemical analyzers and supplies, under a $1.22 million indefinite delivery vehicle extending through September 30, 2027.

Activity has been sparse and declining — two awards in 2021, one in 2022, three in 2023, one in 2024, and one in 2025 — with obligated dollars representing only 23% of combined potential value across the portfolio. Only one award (the November 2025 Defense Health Agency delivery order, $298 thousand) reaches ultimate completion within the next twenty-four months, creating minimal near-term recompete exposure. The vendor's work is categorized primarily under Medical Laboratories NAICS (28 awards) and Medical and Surgical Instruments, Equipment, and Supplies PSC (40 awards), with secondary activity in diagnostic substance manufacturing and laboratory equipment supply. Performance occurs entirely in Italy to support overseas military medical infrastructure.